Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

1.77
-0.2200-11.06%
Post-market: 1.800.0291+1.64%19:49 EDT
Volume:629.87K
Turnover:1.15M
Market Cap:46.52M
PE:-0.81
High:1.90
Open:1.90
Low:1.71
Close:1.99
52wk High:16.00
52wk Low:1.71
Shares:26.28M
Float Shares:19.19M
Volume Ratio:1.61
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:5.86
PE(LYR):-0.68

Loading ...

Elicio Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Jun 16

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Reuters
·
Jun 16

Top Midday Decliners

MT Newswires Live
·
Jun 16

Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal

Reuters
·
Jun 15

Elicio selloff brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Jun 15

Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan

TIPRANKS
·
Jun 15

Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 15

Elicio Therapeutics Shares Fall After Missing Primary Endpoint in Pancreatic Cancer Trial

MT Newswires Live
·
Jun 15

Elicio Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $23 From $17

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Shares Fall 50% Premarket After Co Reports Mid-Stage Data for Its Experimental Pancreatic Cancer Therapy

THOMSON REUTERS
·
Jun 15

BUZZ-Elicio Therapeutics tumbles as pancreatic cancer vaccine misses main goal of trial

Reuters
·
Jun 15

Elicio says Phase 2 AMPLIFY-7P trial of ELI-002 7P misses primary DFS endpoint in adjuvant pancreatic cancer

Reuters
·
Jun 15

Elicio Therapeutics - Eli-2 7P Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics Reports Results From Phase 2 Amplify-7P Study and Outlines Refined Phase 3 Development Strategy for Eli-002 7P in Adjuvant Pancreatic Cancer

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Evaluating Strategic Financing and Partnering Opportunities

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - to Focus Phase 3 Development on R0 Resected Population With Additional Eli-2 7P Dosing

THOMSON REUTERS
·
Jun 15

Elicio Therapeutics - Amplify-7P Phase 2 Study Does Not Meet Primary Dfs Endpoint in Intent-to-Treat Population

THOMSON REUTERS
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

Elicio Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
Jun 11

U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle

Reuters
·
Jun 10